Clinical Efficacy of Albumin Paclitaxel Combined with Tegafur Neoadju-vant Chemotherapy in Locally Advanced Gastric Cancer
Objective To investigate the clinical efficacy of albumin paclitaxel combined with Tigioneoadjuvant che-motherapy in the treatment of patients with locally advanced gastric cancer.Methods A total of 82 patients with lo-cally advanced gastric cancer admitted to Putian First Hospital from February 2019 to June 2021 were conveniently selected as the research objects.According to different treatment methods,they were divided into control group and observation group,with 41 cases in each group.The control group was treated with FLOT chemotherapy,the observa-tion group was treated with albumin paclitaxel combined with tegafur neoadjuvant chemotherapy.The clinical efficacy,survival time and incidence of adverse reactions were compared between patients in groups.Results There was no sig-nificant difference in clinical efficacy,significant pathological remission,complete pathological remission,overall sur-vival time and progression-free survival between the two groups(all P>0.05).The incidence of leukopenia 4.88%(2/41)and neutropenia 12.20%(5/41)in the observation group were lower than 21.95%(9/41),31.71%(13/41)in the control group,and the differences were statistically significant(χ2=5.144,4.555,both P<0.05).Conclusion Albumin paclitaxel combined with Tigioneoadjuvant chemotherapy has significant clinical efficacy in the treatment of locally ad-vanced gastric cancer patients,and the incidence of adverse reactions is significantly reduced,and the clinical appli-cation value is high.
Albumin-bound paclitaxelTegafurNeoadjuvant chemotherapyLocally advanced gastric cancer
NETL
NSTL
万方数据
